Heidi Peters, NP
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 193 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AstraZeneca at 29.5% of the total. Among family clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $34.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$750
- GSK$660
- Sanofi$536
- Pharming Healthcare, Inc.$290
- Grifols USA, LLC$258
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,62399%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $1,967 |
| Regeneron Healthcare Solutions, Inc. | 14 | $750 |
| GSK | 30 | $660 |
| Sanofi | 13 | $536 |
| Pharming Healthcare, Inc. | 4 | $290 |
| Grifols USA, LLC | 13 | $258 |
| LEO Pharma Inc. | 4 | $245 |
| Blueprint Medicines Corporation | 3 | $241 |
| Incyte Corporation | 3 | $223 |
| Galderma Laboratories, L.p. | 6 | $175 |
| CSL Behring | 7 | $162 |
| Ionis Pharmaceuticals, Inc. | 2 | $136 |
| Phathom Pharmaceuticals, Inc. | 1 | $127 |
| Optinose US, Inc. | 4 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $111 |
| Amgen | 4 | $96 |
| Genentech USA, Inc. | 4 | $88 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $70 |
| Kaleo, Inc. | 3 | $69 |
| Novartis | 3 | $57 |
| AbbVie | 2 | $53 |
| ADMA Biomanufacturing LLC | 2 | $42 |
| Boehringer Ingelheim | 2 | $36 |
| Verona Pharma, Inc. | 1 | $29 |
| Insmed, Inc. | 1 | $29 |
| Pfizer | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Organon | 3 | $18 |
| Mylan Specialty L.p. | 1 | $16 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,657 in reported general payments places this provider in the 95th percentile of 809 family providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $43,419 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $22,747 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $5,451 |
| Arnuity ElliptaFluticasone Furoate | 14 | $5,290 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,407 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $4,350 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,316 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $4,103 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $2,640 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 83 | $2,166 |
| Olopatadine Hcl | 16 | $2,093 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $1,564 |
| Montelukast Sodium | 171 | $1,386 |
| Cyclophosphamide | 12 | $1,275 |
| Ventolin HfaAlbuterol Sulfate | 17 | $1,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $660 | $53,02489 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,967 | $27,15441 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Idaho.
Other family in Boise
- Jessica BraksiekBoise$41K
- Travis BlaserBoise$33K
- Devon MoserBoise$11K
- Jeffrey RobbinsBoise$9K
- Morgann EasonBoise$7K
- Lori RishelBoise$7K
- Michelle ChinBoise$6K
- Nancy JordanBoise$6K
- Jillian VaughanBoise$6K
- Samantha BoothBoise$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.